For the quarter ended September 30, 2013, Aratana reported a net loss of $4.7 million, or $(0.22) per share, compared with a net loss of $3.2 million, or $(9.64) per share for the quarter ended September 30, 2012. For the nine months ended September 30, 2013, Aratana reported a net loss of $11.4 million, or $(1.50) per share, compared with a net loss of $8.9 million, or $(28.79) per share for the nine months ended September 30, 2012.
As of September 30, 2013, Aratana had a total of approximately $52.3 million in cash, cash equivalents and marketable securities.
2013 Financial Guidance
Aratana affirms prior guidance that we will end the year with $45 million-$50 million in cash and cash equivalents, which the company expects to be sufficient to fund operations to the end of 2015.
Conference Call and Webcast Date:
Thursday, November 14, 2013
8:00 a.m. Eastern Time
Conference call numbers:
Webcast: via the Investor Relations section of the Company's website at aratana.investorroom.com
A replay of the conference call and webcast will be available beginning approximately two hours after the completion of the call through February 10, 2014. Access numbers for this replay are (877) 344-7529 (U.S./Canada) and (412) 317-0088 (international); conference ID: 10036572.
About Aratana Therapeutics
Aratana Therapeutics is a biopharmaceutical company focused on the licensing, development and commercialization of innovati
|SOURCE Aratana Therapeutics, Inc.|
Copyright©2012 PR Newswire.
All rights reserved